First patient dosed in IPH6101/SAR443579 Phase 1/2 clinical trial in various blood cancers
Monalizumab combined with cetuximab and durvalumab demonstrates anti-tumor activity in first-line recurrent or metastatic head and neck cancer at ESMO Immuno-Oncology 2021 Congress
Innate Pharma to present monalizumab data at ESMO Immuno-Oncology 2021 Congress
Innate Pharma to participate in the Evercore ISI 4th Annual Healthconx Virtual Conference
Innate Pharma Third Quarter 2021 Report
Innate Pharma highlights new NK cell engager data with partner Sanofi at SITC annual meeting
Innate Pharma announces Conference Call and Webcast for Q3 2021 Business Update
Innate Pharma 2022 Financial Calendar
Number of shares and voting rights of Innate Pharma as of October 1, 2021
Number of shares and voting rights of Innate Pharma as of September 1, 2021
